Your browser doesn't support javascript.
Evaluation of ten (10) SARS-CoV-2 rapid serological tests in comparison with WANTAI SARS-CoV-2 ab ELISA in Burkina Faso, West Africa.
Ouedraogo, Henri Gautier; Zoure, Abdou Azaque; Compaoré, Tegwinde Rebeca; Ky, Herve; Zida, Sylvie; Zingué, Dezemon; Ouedraogo, Oumarou; Soubeiga, Serge Théophile; Sagna, Tani; Dabiré, Charlemagne; Kambiré, Dinanibè; Zongo, Dramane; Yonli, Albert Théophane; Nikiema, Abdoul Rahamani; Nezien, Désiré; Bansé, Gnintassa Cyrille; Bicaba, Brice Wilfried; Perier, Sophie; Sawadogo, Charles; Yabre, Zakariya; Sangare, Lassana.
  • Ouedraogo HG; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso. whgautier@yahoo.fr.
  • Zoure AA; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Compaoré TR; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Ky H; Unité de Formation et de Recherche en Sciences de la Santé (UFR-SDS), Université Joseph Ki-Zerbo, Ouagadougou, Burkina Faso.
  • Zida S; Direction des Laboratoires de Biologie Médicale (DLBM), Ministère de la santé et de l'Hygiène publique, Ouagadougou, Burkina Faso.
  • Zingué D; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Ouedraogo O; Institut National de Santé Publique (INSP), Ministère de la santé et de l'Hygiène publique, Ouagadougou, Burkina Faso.
  • Soubeiga ST; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Sagna T; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Dabiré C; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Kambiré D; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Zongo D; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Yonli AT; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Nikiema AR; Centre de Recherche Biomoléculaire Pietro Annigoni (CERBA), Ouagadougou, Burkina Faso.
  • Nezien D; Biomedical Research Laboratory (LaReBio)/Biomedical and Public Health Department, Institut de Recherche en Sciences de la Santé (IRSS), Centre National de la Recherche Scientifique et Technologique (CNRST), 03 BP 7047, Ouagadougou, Burkina Faso.
  • Bansé GC; Laboratoire National de Santé Publique (LNSP), Ministère de la Santé et de l'Hygiène Publique, Ouagadougou, Burkina Faso.
  • Bicaba BW; Clinique Notre Dame de la Paix, Ouagadougou, Burkina Faso.
  • Perier S; Centre des Opérations de Réponses aux Urgences Sanitaires (CORUS) /Ministère de la Santé et de l'Hygiène Publique, , Ouagadougou, Burkina Faso.
  • Sawadogo C; Clinton Health Access Initiative (CHAI), Regional offfice, Dakar, Senegal.
  • Yabre Z; Direction des Laboratoires de Biologie Médicale (DLBM), Ministère de la santé et de l'Hygiène publique, Ouagadougou, Burkina Faso.
  • Sangare L; Direction des Laboratoires de Biologie Médicale (DLBM), Ministère de la santé et de l'Hygiène publique, Ouagadougou, Burkina Faso.
Virol J ; 20(1): 57, 2023 03 30.
Article in English | MEDLINE | ID: covidwho-2275191
ABSTRACT

BACKGROUND:

The aim of this study was to evaluate the performance of ten (10) SARS-CoV-2 serological rapid diagnostic tests in comparison with the WANTAI SARS-CoV-2 Ab ELISA test in a laboratory setting. MATERIALS AND

METHODS:

Ten (10) SARS-CoV-2 serological rapid diagnostic tests (RDTs) for SARS-CoV-2 IgG/IgM were evaluated with two (2) groups of plasma tested positive for one and negative for the other with the WANTAI SARS-CoV-2 Ab ELISA. The diagnostic performance of the SARS-CoV-2 serological RDTs and their agreement with the reference test were calculated with their 95% confidence intervals.

RESULTS:

The sensitivity of serological RDTs ranged from 27.39 to 61.67% and the specificity from 93.33 to 100% compared to WANTAI SARS-CoV-2 Ab ELISA test. Of all the tests, two tests (STANDARD Q COVID-19 IgM/IgG Combo SD BIOSENSOR and COVID-19 IgG/IgM Rapid Test (Zhejiang Orient Gene Biotech Co., Ltd)) had a sensitivity greater than 50%. In addition, all ten tests had specificity greater than or equal to 93.33% each. The concordance between RDTs and WANTAI SARS-CoV-2 Ab ELISA test ranged from 0.25 to 0.61.

CONCLUSION:

The SARS-CoV-2 serological RDTs evaluated show low and variable sensitivities compared to the WANTAI SARS-CoV-2 Ab ELISA test, with however a good specificity. These finding may have implications for the interpretation and comparison of COVID-19 seroprevalence studies depending on the type of test used.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Country/Region as subject: Africa Language: English Journal: Virol J Journal subject: Virology Year: 2023 Document Type: Article Affiliation country: S12985-023-02011-4

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Diagnostic study / Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Country/Region as subject: Africa Language: English Journal: Virol J Journal subject: Virology Year: 2023 Document Type: Article Affiliation country: S12985-023-02011-4